Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 4;9(2):e70077.
doi: 10.1002/hem3.70077. eCollection 2025 Feb.

Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study

Mariana Bastos-Oreiro  1 , Gloria Iacoboni  2   3   4 , Víctor N Garcés  2 , Ana C Caballero  5 , Nuria Martínez  6 , Javier Delgado  7 , Aitana Balaguer  8 , Mi Kwon  1 , Sonia Gonzalez de Villambrosia  9 , Rafael Hernani  10 , Ana Jimenez-Ubieto  11 , Rebeca Bailen  1 , Izaskun Zaberio  12 , Alejandro Martín García-Sancho  13 , Pere Barba  2
Affiliations

Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study

Mariana Bastos-Oreiro et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Mariana Bastos‐Oreiro: Honoraria and/or travel support from Abbvie, Bristol‐Myers Squibb, Kite/Gilead, and Novartis. Gloria Iacoboni: Honoraria and/or travel support from Abbvie, AstraZeneca, Autolus, Bristol‐Myers Squibb, Kite/Gilead, Miltenyi, and Novartis. Víctor N. Garcés: No disclosures. Ana C. Caballero: No disclosures. Javier Delgado: No disclosures. Aitana Balaguer: No disclosures. Mi Kwon: Honoraria and/or travel support from Kite/Gilead, Novartis. Sonia Gonzalez de Villambrosia: Honoraria and/or travel support from Abbvie, Roche, Incyte, Bristol‐Myers Squibb, Kite/Gilead, Miltenyi, and Novartis. Ana Jimenez‐Ubieto: Honoraria and/or travel support from Abbvie, Roche, Incyte, Kite/Gilead, Miltenyi, and Novartis. Rebeca Bailen: Honoraria and/or travel support from Incyte, Bristol‐Myers Squibb, Kite/Gilead, Miltenyi, and Novartis. Alejandro Martín García‐Sancho: Honoraria and/or consulting fees: Roche, BMS, Takeda, Janssen, Kyowa Kirin, Gilead/Kite, Incyte, Lilly, Miltenyi, Ideogen, Genmab, Abbvie, Sobi, Astra‐Zeneca, GSK, Regeneron. Pere Barba: Honoraria and/or travel support from Abbvie, AstraZeneca, Autolus, Bristol‐Myers Squibb, Kite/Gilead, Miltenyi, and Novartis.

Figures

Figure 1
Figure 1
Outcome of patients treated with CAR‐T therapy, highlighting the lymphoma stage, type of product, lymphoma risk, response obtained, relapse, and current situation.
See this image and copyright information in PMC

References

    1. Bastos‐Oreiro M, Abrisqueta P, Gutierrez A, et al. New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: analysis from the RELINF registry of the GELTAMO group. HemaSphere. 2024;8(4):e70. - PMC - PubMed
    1. El Weshi A, Akhtar S, Mourad WA, et al. T‐cell/histiocyte‐rich B‐cell lymphoma: clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Leuk Lymphoma. 2007;48(9):1764‐1773. - PubMed
    1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720‐1748. - PMC - PubMed
    1. Campo E, Jaffe ES, Cook JR, et al. The International Consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229‐1253. - PMC - PubMed
    1. Griffin GK, Weirather JL, Roemer MGM, et al. Spatial signatures identify immune escape via PD‐1 as a defining feature of T‐cell/histiocyte‐rich large B‐cell lymphoma. Blood. 2021;137(10):1353‐1364. - PMC - PubMed

LinkOut - more resources